BostonGene, developer of the leading AI foundation model for cancer and the immune system, today announced seven abstracts have been accepted for presentation at the San Antonio Breast Cancer ...
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback